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INtRoDUCtIoN
Heredity is a major risk factor for colorectal cancer (CRC). Identification of individuals and families 
at increased risk allows for targeted surveillance, which has been shown to reduce morbidity and 
mortality from CRC (1, 2).
Lynch syndrome is a multi-tumor syndrome with particularly high risks for colorectal, endome-
trial, and ovarian cancer (3–6). The syndrome is caused by germline DNA-mismatch repair (MMR) 
gene mutations with major contributions from MLH1 (MIM#120436) (42%), MSH2 (MIM#609309) 
(33%), MSH6 (MIM#600678) (18%), and PMS2 (MIM#600259) (8%). Only about one-third of the 
Lynch syndrome families fulfill the Amsterdam criteria (AC) (7–9). The cumulative incidence of any 
cancer at 70 years of age is 72% for MLH1 and MSH2 mutation carriers but lower in MSH6 (52%) 
and PMS2 (18%) mutation carriers. MSH6 and PMS2 carriers developed no cancers before 40 years 
of age (10).
Mutation screening in a relatively large proportion of South American families with suspected 
Lynch syndrome has recently identified 99 disease-predisposing mutations in MLH1 and MSH2, 
which mutation spectrum is predominated by MLH1 (60%) and MSH2 (40%). Among the reported 
mutations, genetic hot-spot regions, new and potential founder mutations have been described in 
the South American population (11, 12).
Several genome-wide association studies have identified single nucleotide polymorphisms (SNPs) 
in at least 15 independent loci associated with CRC risk (odds ratio ranging from 1.10 to 1.26 per risk 
allele) (13–15). Although there is no evidence that these SNPs associated with CRC in the general 
population are modifiers of the risk for MMR gene mutation carriers overall and therefore any 
evidence of proven clinical utility in Lynch syndrome (16).
The MLH1 Ile219Val (rs1799977) is a common germline alteration, located in exon 8 at the 
nucleotide 655. This polymorphism has been described in a high frequency of the South American 
Lynch syndrome population, but no modifier effect of CRC risk and MMR disease-predisposing 
mutation carriers was observed (17). However, it has been reported to confer a twofold-increased 
risk of CRC development in sporadic Mexican patients (18). Other conditions that have been 
associated with this polymorphism include childhood acute lymphoblastic leukemia, breast cancer, 
radiation-induced rectal or bladder toxicity, and ulcerative colitis (19–23). It is unknown whether the 
MLH1 Ile219Val polymorphism has an effect on cancer risk and in the MMR capacity in Argentinean 
families with suspected Lynch syndrome. Thus, we aim to determine its frequency, its correlation 
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with disease-predisposing MMR gene mutations, and to delineate 
the clinical characteristics from these families.
patIeNtS aND MetHoDS
ethics Statement
The study was performed in compliance with the Helsinki 
Declaration and approved by the Ethics Committee of the Hospital 
Italiano de Buenos Aires in Argentina. Written informed consent 
was obtained from all participants during genetic counseling 
sessions.
patient Selection
The Hereditary cancer registry of the Hospital Italiano de Buenos 
Aires is a national Argentinean registry that contains informa-
tion of all families identified with proven or suspected hereditary 
cancer. Through research collaborations, data from the registry 
is freely available. This prospective database contains clinical, 
molecular, and familial data, which is clinically relevant. In 
addition, the electronic medical records of these patients can be 
reviewed to retrieve further data.
We obtained molecular (genetic testing) and epidemiological 
data (family history) from 48 families that fulfilled AC (n = 33), 
Bethesda guidelines criteria (n = 8), and families suggestive of a 
dominant CRC inheritance syndrome (n = 7) (7, 8, 24) between 
2009 and 2016. Family pedigree was constructed based on the 
information provided by the proband during one or more genetic 
counseling sessions.
Disease-predisposing MMR Gene 
Mutations and Nomenclature
Germline mutation screening of MLH1, MSH2, MSH6, and PMS2 
was performed by next generation sequencing platform using the 
personal genome machine® system (PGM, LT) according to the 
manufacturer’s instructions. Mutation nomenclature followed 
the Human Genome Variation Society (HGVS) guidelines.1 
All identified mutations were compared to previously reported 
in MMR databases, maintained by the International Society 
for Gastrointestinal Hereditary Tumors2 and the French MMR 
network.3
Statistical analysis
Age comparison between the groups was performed using Mann–
Whitney U-test. In the tables, results were expressed, as mean 
age ± SD. Significance for expected frequencies was tested using 
Chi-squared test. The analyses were performed using Statview 
(SAS Institute Inc. 100 SAS Campus Drive Cary, NC 27513-2414, 
USA) and Chi-squared Calculator (Social Science Statistics4). For 
all tests, p < 0.05 was considered statistically significant.
1www.hgvs.org/mutnomen/
2http://www.insight-group.org 
3http://www.umd.be/UMD_Central/ 
4http://www.socscistatistics.com 
ReSULtS
Overall, forty-eight hereditary CRC families were identified from 
the Hereditary cancer register of the Hospital Italiano de Buenos 
Aires. Of them, 19/48 (40%) of the families carried disease-
predisposing mutations in the MMR genes. The mean age at first 
diagnosis in Lynch syndrome families was 42 ± 7.3 years (range 
27–55). Mutations in MLH1 and MSH2 genes were identified in 
17/33 (52%) of the families that fulfilled the AC. However, no 
disease-predisposing mutations in MSH6 and PMS2 genes were 
found in this series (Table 1). Mutational and clinical information 
from the Argentinean Lynch syndrome families is described in 
Table 1.
When we analyzed the genotypic and allelic frequencies of 
the MLH1 Ile219Val polymorphism, we found Val-carriers in 
44% (21/48) of the Argentinean families with suspected of Lynch 
syndrome. Of them, 95% (20/21) were Ile/Val heterozygotes and 
5% (1/21) were Val/Val homozygotes. The allelic frequency of Ile 
and Val were 0.77 and 0.23, respectively (Table 2).
Regarding the clinical characteristics, a slightly early mean 
age at CRC and endometrial cancer diagnoses was observed 
in the families without the MLH1 Ile219Val polymorphism in 
comparison to the families harboring the MLH1 polymorphism 
(45 and 44 years vs. 49 and 46 years, respectively) (p > 0.05). The 
presence of AC and Bethesda guidelines was not associated with 
the MLH1 Ile219Val polymorphism (p  >  0.05). As expected, 
CRC and endometrial cancer were the most frequent tumors 
among the MLH1 Ile219Val carriers and non-carriers. While skin 
tumors were observed in both groups of families, breast and small 
intestine tumors were observed only in the non-MLH1 Ile219Val 
families.
Of the 21 families with the MLH1 Ile219Val polymorphism, 
5 (24%) harbored disease-predisposing MMR gene mutations; 
MLH1 was the most affected gene occurring in 4/5 (80%) of 
the cases. In the 27 non-MLH1 Ile219Val polymorphism fami-
lies, 14 (52%) harbored MLH1 or MSH2 disease predisposing 
mutations; MHS2 the most frequently affected gene occurring 
in 10 of them (71%) (available upon request). In the group of 
MLH1 Ile219Val polymorphism (n = 21) that displayed disease-
predisposing MMR gene mutations (n =  5/21), the Val-allele 
was significantly associated with MLH1 and/or MSH2 muta-
tions (p < 0.05).
In addition, we analyzed the clinical features of the 21 families 
harboring MLH1 Ile219Val polymorphism in the presence of 
disease-predisposing MMR gene mutations, MMR carrier’s 
families showed an early mean age at CRC diagnosis (41 ± 5.35) 
years, although these differences were not significant (p > 0.05) 
(available upon request).
In order to evaluate if the MLH1 Ile219Val polymorphism 
exerts any influence at the age of CRC onset, we analyzed the 
mean age at CRC diagnosis of families harboring or not the 
MLH1 Ile219Val polymorphism according to their MMR status 
(MLH1 or MSH2). The MLH1 Ile219Val polymorphism group 
(n  =  21), which harbored disease-predisposing mutations in 
MLH1, or MSH2 showed a mean age at CRC onset of 42.3 and 
37 years, respectively. In the non-MLH1 Ile219Val carriers, the 
mean age among those who displayed the mutations was 38.3 
taBLe 2 | Genotypic and allelic frequency of the MLH1 I219V 
polymorhism in argentinean families with suspected Lynch syndrome.
polymorphism Genotype N+/N  
total 
Genotypic  
frequency 
allelic 
frequency
Ile/Ile 27/48 0.56
I219V Ile/Val 20/48 0.42 0.77
C.655 A > G Val/Val 1/48 0.02 0.23
Ile/Ile: homozygosis for the wild allele; Ile/Val: heterozygosis; Val/Val: homozygosis for 
the polymorphic allele; N+: positive cases for each genotype; N total: total number of 
the evaluated individuals.
taBLe 1 | Disease-predisposing MMR gene mutations in argentinean Lynch syndrome families.
Family  
ID
Gene Nucleotide Consequence exon Reported as Clinical  
criteria
Cancer (age)
52 MLH1 c.199 G > A p.G67R 2 Causal ACI No cancers
6 MLH1a c.676 C > T p.R226X 8 Causal ACI CRC (36)
8 MLH1 c.677 G > A p.R226Q 8 Causal ACI CRC (38), EC (52)
DE MLH1 c.677 + 5 G > A 8i Likely causal ACI CRC (27), BC (29)
B MLH1a c.1852_1854 delAAG p.K618del 16 Causal ACI EC (39), CRC (47)
50 MLH1a c.1852_1854 delAAG p.K618del 16 Causal Bethesda CRC (44)
2 MLH1 c.1890Dup p.D631fsX1 16 Causal ACI CRC (50)
P MLH1a c.2252_2253delAA p.K751SfsX3 19 Causal ACI EC (52)
DO MSH2 c(?_−0.68)_211+?del 1 Causal ACI CRC (55)
51 MSH2a c(?_−0.68)_211+?del 1 Causal ACI CRC (37), EC (46)
4 MSH2 c.166 G > T p.E56X 1 Causal ACI CRC (44), EC (51)
3 MSH2 c.289 C > T p.Q97X 2 Causal ACI CRC (49), SKC (51), UT (52)
SS MSH2 c.484 G > A p.G162Arg 2 Causal ACII No cancers
49 MSH2 c.388_389delCA p.Q130ValfsX2 3 Causal ACI CRC (51), SKC (48), SIC (65)
DA MSH2 c.1046C > G p.P349R 6 Causal ACI BC (41)
L MSH2 c.1662-2A > G 10i Likely causal Bethesda CRC (42)
N MSH2 c.1861C > T p.R621X 11 Causal ACII EC (34), CRC (59), SIC (79)
45 MSH2 c.1910delC p.R638GfsX47 12 Causal ACII CRC (39), EC (41), SIC (44), BC (49)
5 MSH2 c.2046_2047 delTG p.V684DfsX14 13 Causal ACII CRC (42)
aMLH1 I219V polymorphism.
CRC, colorectal cancer; EC, endometrial cancer; BC, breast cancer; SKC, skin cancer; UT urinary tract career; SIC, small intestine cancer; AC, Amsterdam criteria.
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and 47.6 years, respectively. However, no statistically significant 
association was found between these groups (available upon 
request).
DISCUSSIoN
In the Argentinean suspected Lynch syndrome families, the 
genetic polymorphism (Ile219Val) in the MLH1 gene was found 
in 44% of the population, which fits with the previous genetic stud-
ies that reported an incidence of 31–80% from different popula-
tions (17, 24–26). The allelic frequencies for Ile and Val (0.77 and 
0.23) were similar to the reports from South American suspected 
Lynch syndrome families (0.7 and 0.3), German Lynch syndrome 
families (0.69 and 0.31), Swedish Lynch syndrome families (0.64 
and 0.34), and Italian suspected Lynch syndrome families (0.33 
for Val) (17, 24–27). This similarity may be explained by the influ-
ence of European ancestors in the South American population, 
particularly in Brazil, Uruguay, and Argentina (11). However, 
our allelic frequencies are slightly higher than the minor allele 
frequency (MAF) reported by the 1000 Genomes Project (0.87 
and 0.13, respectively) although similar to Puerto Rico when 
analyzed into the American population (28).
In the current study, no association was observed between the 
MLH1 Ile219Val polymorphism and cancer risk. This is consist-
ent with several functional analyses indicating that the variant has 
binding properties to PMS2 and DNA repair efficiency similar 
to the wild type (29, 30). A recent CRC meta-analysis including 
8068 cases and 6568 controls from Australia, Czech Republic, 
Spain, Germany, and Sweden with frequencies of 0.678 and 
0.671, respectively, found not associations of CRC risk and MLH1 
Ile219Val polymorphism (31). However, Kim et  al. suggested 
that the homozygosity for the 219V variant was correlated with 
a significantly reduced MLH1 expression among sporadic CRC 
cases (32). The difference might be a reflection of environmental 
impact on gene distribution, ethnic background or small-sized 
family cohort (33–35).
We found that the absence of the MLH1 Ile219Val polymor-
phism was associated with an early mean age at CRC cancer 
diagnosis, and the development of breast tumors was the main 
clinical features. This is in line with the Brazilian hereditary 
non-polyposis colorectal cancer (HNPCC) familial study that 
reported that breast cancer followed by endometrial and uter-
ine cervix cancer are the most frequent extracolonic tumors 
found in women (36). Although, this is a small increase in 
breast cancer risk, it might point out interesting biological 
connections.
Regarding the association of the MLH1 Ile219Val poly-
morphism and disease-predisposing MMR gene mutations, 
we described a lower frequency (24%) of disease-predisposing 
MMR gene mutations compared to the reported by the South 
American Lynch syndrome families (33%) (17). In families 
harboring the MLH1 Ile219Val polymorphism and disease-
predisposing MMR mutations, MLH1 was the most affected 
gene. The seemingly unique contribution than the 57 (MLH1) 
and 43% (MSH2) reported by the South American population 
could reflect random variation, population structure, size sample 
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and genetic heterogeneity (17). In this series, we found a statisti-
cally significant link between the presence of the MLH1 Ile219Val 
polymorphism and disease-predisposing MMR gene mutations 
carriers, which suggest that these genetic discriminators may be 
relevant for molecular diagnostics in this population. However, 
our study has a limited sample size and the results need further 
validation. Studies with larger sample size are needed to further 
evaluate the role of this polymorphism.
In summary, our findings point to a high frequency of the 
MLH1 Ile219Val polymorphism in the Argentinean families 
with suspected Lynch syndrome and its modifier effect with 
the disease-predisposing MLH1/MSH2 genes mutations. Our 
data may provide important clues to contribute to molecular 
diagnostics, improved risk stratification, and targeted therapeutic 
strategies in hereditary CRC.
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